2022-002816-22: A study of Visugromab (CTL-002) in combination with immunotherapy, in patients with muscle invasive bladder cancer Uno studio di Visugromab (CTL-002) in combinazione con l'immunoterapia, in pazienti con tumore della vescica muscolo-invasivo |
|
|
| Not yet recruiting | 2 | 30 | Europe | OPDIVO 10 mg/mL concentrate for solution for infusion, Visugromab, [-], [CTL-002], Concentrate for solution for infusion, Opdivo | Catalym GmbH, CatalYm GmbH | Muscle invasive bladder cancer set to undergo radical cystectomy who cannot receive or refuse to receive cisplatin-based chemotherapy carcinoma vescicale muscolo-invasivo da sottoporre a cistectomia radicale, per chi non può ricevere o rifiuta la chemioterapia con cisplatino., A therapy for the muscle-invasive bladder cancer (which is a tumor grown into the muscle of the bladder) for people who cannot receive or refuse to receive chemotherapy based on cisplatin Una terapia per il tumore della vescica muscolo-invasivo (che è un tumore cresciuto nel muscolo della vescica) per chi non può ricevere o rifiuta la chemioterapia con cisplatino, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 2 | 30 | Europe | Nivolumab, Visugromab (CTL-002), Placebo | CatalYm GmbH, CatalYm GmbH | Bladder Cancer, Adult Solid Tumor | 04/25 | 04/26 | | |
2020-002103-19: Phase 1/2 FIH trial of CTL-002 in subjects with advanced-stage, relapsed/refractory solid tumors. |
|
|
| Not yet recruiting | 1/2 | 162 | Europe | OPDIVO 10 mg/mL concentrate for solution for infusion, CTL-002, Concentrate for solution for infusion, Opdivo® | CatalYm GmbH, CatalYm GmbH | Advance-stage, relapsed/refractory solid tumors in non-curable state, that relapsed post or were refractory to a prior anti-PD-1/PD-L1 therapy., Advanced-stage, relapsed/refractory solid tumors, Diseases [C] - Cancer [C04] | | | | |
